These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6230369)

  • 1. Effectiveness of the antimicrobial removal device, BACTEC 16B medium, and thiol broth in neutralizing antibacterial activities of imipenem, norfloxacin, and related agents.
    Weinberg E; Shungu DL; Gadebusch HH
    J Clin Microbiol; 1984 Feb; 19(2):207-9. PubMed ID: 6230369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of Bordetella pertussis to doxycycline, cinoxacin, nalidixic acid, norfloxacin, imipenem, mecillinam and rifampicin.
    Zackrisson G; Brorson JE; Björnegård B; Trollfors B
    J Antimicrob Chemother; 1985 May; 15(5):629-32. PubMed ID: 2861190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.
    Barry AL; Jones RN; Thornsberry C; Ayers LW; Gerlach EH; Sommers HM
    Antimicrob Agents Chemother; 1984 May; 25(5):633-7. PubMed ID: 6233935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of norfloxacin in synthetic media and human urine compared to that of cinnoxacin, nalidixic acid and pipemidic acid.
    Shah PM; Ottnad-Walz M; Stille W
    Methods Find Exp Clin Pharmacol; 1983 Dec; 5(10):731-4. PubMed ID: 6231438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro effect of pH and glucose concentration on the antibacterial activity of norfloxacin in urine.
    Fromtling RA; Abruzzo GK; Gadebusch HH
    Methods Find Exp Clin Pharmacol; 1984 Dec; 6(12):737-41. PubMed ID: 6241649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.
    Neu HC; Labthavikul P
    Antimicrob Agents Chemother; 1982 Jul; 22(1):23-7. PubMed ID: 6214995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.
    Barry AL; Jones RN
    Antimicrob Agents Chemother; 1984 Jun; 25(6):775-7. PubMed ID: 6234858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
    Vuye A
    Arzneimittelforschung; 1983; 33(12):1623-7. PubMed ID: 6230083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antibacterial activity of imipenem against Pseudomonas and Staphylococcus species. Comparison with thirteen other antimicrobial agents.
    Cristiano P; Abbate GF; Alagia I; Leonessa V; Giaquinto E; Savioli L
    Drugs Exp Clin Res; 1985; 11(1):39-48. PubMed ID: 3869802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activity of norfloxacin.
    Norrby SR; Jonsson M
    Antimicrob Agents Chemother; 1983 Jan; 23(1):15-8. PubMed ID: 6219617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antibacterial activity of norfloxacin compared with eight other antimicrobial agents.
    Body BA; Fromtling RA; Shadomy S; Shadomy HJ
    Eur J Clin Microbiol; 1983 Jun; 2(3):230-4. PubMed ID: 6224678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of Mycobacterium fortuitum to N-formimidoyl thienamycin and several cephamycins.
    Cynamon MH; Palmer GS
    Antimicrob Agents Chemother; 1982 Dec; 22(6):1079-81. PubMed ID: 6961887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
    Reeves DS; Bywater MJ; Holt HA; White LO
    J Antimicrob Chemother; 1984 Apr; 13(4):333-46. PubMed ID: 6233250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of the in vitro activity of norfloxacin and other drugs on amoxicillin-resistant uropathogenic isolates.
    Piccolomini R; Allocati N; Catamo G
    Chemioterapia; 1984 Jun; 3(3):167-72. PubMed ID: 6241505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of HR 810, a new cephalosporin.
    Bertram MA; Bruckner DA; Young LS
    Antimicrob Agents Chemother; 1984 Aug; 26(2):277-9. PubMed ID: 6593000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outer membrane permeability of imipenem in comparison with other beta-lactam antibiotics.
    Hashizume T; Yamaguchi A; Sawai T
    J Antibiot (Tokyo); 1986 Jan; 39(1):153-6. PubMed ID: 3512504
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro antibacterial activity of norfloxacin (MK-0366).
    King A; Warren C; Shannon K; Phillips I
    Antimicrob Agents Chemother; 1982 Apr; 21(4):604-7. PubMed ID: 6211139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of antibiotic removal by the antibiotic-binding blood culture systems.
    Smith SM; Eng RH
    Diagn Microbiol Infect Dis; 1985 May; 3(3):201-12. PubMed ID: 3888507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in-vitro activity of Sch 34343, imipenem, cefpirome and cefotaxime.
    Bauernfeind A
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():155-64. PubMed ID: 3897170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belgian multicenter in vitro study of norfloxacin.
    Verbist L
    Acta Clin Belg; 1985; 40(3):167-73. PubMed ID: 3161262
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.